Quality control and safety assessment of BCG vaccines in the post-genomic era

References

• World Health Organization. Vaccine-preventable diseases: monitoring system 2013 global summary [Internet]. Geneva (Switzerland): World Health Organization; c2013. WHO-UNICEF Estimates of BCG Coverage. 2013 Jul 14 [cited 2014 May 20]; [about 3 screens]. Available from: http://apps.who.int/immunization_monitoring/en/globalsummary/timeseries/tswucoveragebcg.html
   Google Scholar
• Ho MM, Corbel MJ, Knezevic I, Roumiantzeff M. Report on a WHO consultation on the characterisation of BCG vaccines. Geneva (Switzerland): WHO; -ember2004. Vaccine. 2005;23:5700–5704.
   Google Scholar
• Knezevic I, Corbel MJ. WHO discussion on the improvement of the quality control of BCG vaccines. Pasteur Institute, Paris, France, 7 June 2005. Vaccine.
   Google Scholar
• Knezevic I, Corbel MJ. WHO discussion on the improvement of the quality control of BCG vaccines. Paris (France): Pasteur Institute; 2005. Vaccine. 2006;24:3874–3877.
   Google Scholar
• World Health Organization. Expert committee on biological standardization. Requirements for dried BCG vaccine. 1987, WHO Technical Report Series No. 745; 60–92.
   Google Scholar
• European Pharmacopoea. Directorate for the quality of medicines of the council of Europe (EDQM). BCG vaccine, freeze-dried. Strasbourg. 2008 [01/2008:0163]: 759–761.
   Google Scholar
• Orme IM. Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance in mice inoculated with killed mycobacterial vaccines. Infect Immun. 1988;56:3310–3312.
   PubMed Web of Science ®Google Scholar
• Parra M, Lim YA, Kolibab K, Derrick S, Cadieux N. Development of a murine mycobacterial growth inhibition assay for evaluating vaccines against Mycobacterium tuberculosis. Clin Vaccine Immun. 2009;16:1025–1032.
   PubMed Web of Science ®Google Scholar
• Ho MM, Markey K, Rigsby P, Jensen SE, Gairola S, Seki M. Report of an international collaborative study to establish the suitability of using modified ATP assay for viable count of BCG vaccine. Vaccine. 2008;26:4754–4757.
   PubMed Web of Science ®Google Scholar
• Jensen SE, Hubrechts P, Klein B, Haslov KR. Development and validation of an ATP method for rapid estimation of viable units in lyophilised BCG Danish 1331 vaccine. Biologicals. 2008;36:308–314.
   PubMed Web of Science ®Google Scholar
• Crispen RG. Rapid testing of freeze dried BCG vaccine for stability and viability. Symp Ser Immunobiol Stand. 1971;17:205–210.
   Google Scholar
• Lundin A. Use of firefly luciferase in ATP related assays of biomass, enzymes and metabolites. Methods Enzymol. 2000;305:346–370.
   PubMed Web of Science ®Google Scholar
• Allen RC. In: DeLuca M, McElroy WD, editors. Bioluminescence and chemiluminescence. New York (NY): Academic Press; 1981. p. 63–73.
   Google Scholar
• Askgaard DS, Gottschau A, Knudsen K, Bennedsen J. Firefly luciferase assay of adenosine triphosphate as a tool of quantitation of the viability of BCG vaccines. Biologicals. 1995;23:55–60.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Geneva (Switzerland): Expert committee on biological standardization. In: Recommendations to assure the quality, safety and efficacy of BCG vaccines. 2011. p.1–48.
   Google Scholar
• Meeting report: WHO Informal Consultation on Standardization and Evaluation of BCG Vaccines 2009; Geneva (Switzerland): [cited 2014 May 20]. Available from: http://who.int/biologicals/publications/meetings/areas/vaccines/bcg/BCG_meeting_report_2009v7_FOR_WEB_10JUNE.pdf
   Google Scholar
• Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE 3rd, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998;393:537–544.
   PubMed Web of Science ®Google Scholar
• Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, Rane S, Small PM. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science. 1999;284:1520–1523.
   PubMed Web of Science ®Google Scholar
• Bedwell J, Kairo SK, Behr MA, Bygraves JA. Identification of substrains of BCG vaccine using multiplex PCR. Vaccine. 2001;19:2146–2151.
   PubMed Web of Science ®Google Scholar
• Markey K, Ho MM, Choudhury B, Seki M, Ju L, Castello-Branco LR, Gairola S, Zhao A, Shibayama K, Andre M, Corbel MJ. Report of an international collaborative study to evaluate the suitability of multiplex PCR as an identity assay for different sub-strains of BCG vaccine. Vaccine. 2010;28(43):6964–6969.
   PubMed Web of Science ®Google Scholar
• Castillo-Rodal AI, Castanon-Arreola M, Hernandez-Pando R, Calva JJ, Sada-Diaz E, Lopez-Vidal Y. BCG sub strains confers different protection against Mycobacterium tuberculosis infection in BALB/c model of progressive pulmonary tuberculosis. Infect Immun. 2006;74:1718–1724.
   PubMed Web of Science ®Google Scholar
• Brosch R, Gordon SV, Garnier T, Eiglmeier K, Frigui W, Valenti P, Dos Santos S, Duthoy S, Lacroix C, Garcia-Pelayo C, Inwald JK, Golby P, Garcia JN, Hewinson RG, Behr MA, Quail MA, Churcher C, Barrell BG, Parkhill J, Cole ST. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci. 2007;104:5596–5601.
   Google Scholar
• Stefanova T, Chouchkova M, Hinds J, Butcher P, Inwald J, Dale J. Genetic composition of Mycobacterium bovis BCG substrain Sofia. J Clin Microbiol. 2003;41:5349.
   PubMed Web of Science ®Google Scholar